Data from the ARISTOTLE trial showed that apixaban, compared with warfarin, reduced the rates of stroke, death and major bleeding in patients with atrial fibrillation, regardless of renal function. Is the problem of balancing the risks of thromboembolism and bleeding in patients with atrial fibrillation and chronic kidney disease finally solved?
